Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant factor XIII improves established experimental colitis in rats.

G D'Argenio1, A Grossman, V Cosenza

  • 1Gastrointestinal Unit, School of Medicine, Federico II University, Naples, Italy.

Digestive Diseases and Sciences
|May 5, 2000
PubMed
Summary

Recombinant Factor XIII (FXIII) effectively treats experimental colitis in rats, reducing inflammation and promoting long-lasting healing of both developing and established lesions. This protein shows therapeutic potential for inflammatory bowel diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of peptide receptor radionuclide therapy (PRRT) on the quality of life in patients with neuroendocrine tumours.

Journal of neuroendocrinology·2026
Same author

A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomised clinical study.

Scientific reports·2024
Same author

Peptide Hp(2-20) accelerates healing of TNBS-induced colitis in the rat.

United European gastroenterology journal·2018
Same author

Assessment of public and professional perceptions of access to unscheduled dental care.

British dental journal·2018
Same author

Hearing threshold shifts among military pilots of the Israeli Air Force.

Journal of the Royal Army Medical Corps·2017
Same author

New onset diabetes after kidney transplantation is associated with increased mortality-A retrospective cohort study.

Diabetes/metabolism research and reviews·2017

Area of Science:

  • Biochemistry
  • Gastroenterology
  • Pharmacology

Background:

  • Factor XIII (FXIII) is crucial for fibrin clot stabilization and wound healing.
  • Reduced FXIII levels correlate with increased severity in inflammatory bowel diseases (IBD).
  • FXIII supplementation shows promise in IBD patients resistant to standard treatments.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of intravenous recombinant FXIII (rFXIII) in a rat model of experimental colitis.
  • To confirm rFXIII as the active component in plasma FXIII concentrates.
  • To elucidate the potential of rFXIII for treating human IBD.

Main Methods:

  • Colitis was induced using trinitrobenzenesulfonic acid (TNBS) in male Wistar rats.
  • Rats received daily intravenous rFXIII or vehicle for 10 days, with treatment starting immediately or 7 days post-induction.

Related Experiment Videos

  • Lesion severity was assessed via colon weight, macroscopic, and histologic scores; transglutaminase activity was measured.

    • Main Results:

    • rFXIII significantly reduced the severity of both developing and established colitic lesions.
    • Therapeutic benefits, including improved healing, persisted for at least 18 days after rFXIII treatment cessation.
    • rFXIII administration restored serum and tissue transglutaminase levels.

    Conclusions:

    • Pure rFXIII demonstrated efficacy comparable to plasma FXIII concentrates in experimental colitis.
    • rFXIII effectively promotes healing of pre-existing lesions, a key characteristic for IBD treatment.
    • rFXIII represents a promising therapeutic agent for inflammatory bowel diseases.